Intimation under Regulation 30 of SEBI (LODR) 2015 for inspection of USFDA

Corporate Office & Central Laboratory: Survey No 9/1, Near Tulsiyana Industrial Park, Gram Kumerdi, IndoreMp 453555 Tel: +91 731 4243850 - 88 Email: compliance_officer@choksilab.in Website: www.choksilab.in CIN: L85195MP1993PLC007471 To, Date: 21st August,2026 The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Tower Dalal Street, Fort Mumbai-Maharashtra 400001 Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Ref: Scrip Code: 526546, ISIN: INE493D01013. Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“LODR Regulations”) this is to inform you that the United States Food & Drug Administration (USFDA) had inspected Company’s central laboratory located at Indore. The inspection was carried on between August 17, 2026 to August 20, 2026. On conclusion of the inspection, the Company received 4 (Four) observations. We are addressing the observations comprehensively and will respond to the USFDA within the stipulated timeframe. The Company reaffirms its commitment to fully comply with USFDA regulations and to maintain the highest standards of quality and regulatory compliance at all times. You are requested to take the aforesaid on your record and disseminate the same for information to the public. Thanking You Yours faithfully For Choksi Laboratories Limited Prakhar Dubey Company Secretary & Compliance Officer Mem. No.: A65011